Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd ...

Evolus Inc . (NASDAQ:EOLS), a company specializing in aesthetic products with a market capitalization of $933 million, has recently made significant strides in expanding its product portfolio and ...

HC Wainwright reissued their buy rating on shares of Evolus (NASDAQ:EOLS – Free Report) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $27.00 price ...

Evolus, Inc. announced its preliminary unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The company reported a preliminary unaudited net revenue of $79.0 million for ...

The FDA has approved Evolysse Form and Evolysse Smooth injectable hyaluronic acid gels, two dermal fillers from Evolus, the ...

Evolus, Inc. has announced FDA approval for two new injectable hyaluronic acid gels, Evolysse Form and Evolysse Smooth. These ...

Evolus (EOLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Evolus said on Thursday the U.S. Food and Drug Administration has approved its two new anti-wrinkle injectable gels, expanding the company's product portfolio beyond its cosmetic injection Jeuveau.

Evolus said the Food and Drug Administration approved its injectable hyaluronic acid gels, known as Evolysse Form and Evolysse Smooth, in line with management expectations.